MedTrace Logo

Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

NCT00219765 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2005-11-28

No results posted yet for this study

Summary

The aim of this phase I/II trial is to determine the dose of daunorubicine to be associated with cytarabine and Imatinib for induction therapy in patients with chronic myelogenous leukemia in myeloid acute phase.

Conditions

  • Chronic Myeloid Leukemia

Interventions

DRUG

Imatinib mesylate 600 mg

DRUG

Cytarabine

DRUG

Daunorubicine

Sponsors & Collaborators

  • Ministry of Health, France

    collaborator OTHER_GOV

  • Novartis

    collaborator INDUSTRY

  • Poitiers University Hospital

    lead OTHER

Principal Investigators

  • François GUILHOT, MD · Department of Oncology hematology and Cell therapy, University Hospital , 86021 Poitiers - FRANCE

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Completion
2006-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00219765 on ClinicalTrials.gov